Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5HY92
UPID:
FIGN_HUMAN
Alternative names:
-
Alternative UPACC:
Q5HY92; B3KWM0; Q9H6M5; Q9NVZ9
Background:
Fidgetin, an ATP-dependent microtubule severing protein, plays a crucial role in cellular microtubule dynamics. By severing microtubules along their length and depolymerizing their ends, primarily the minus-end, Fidgetin suppresses microtubule growth from and attachment to centrosomes. This activity is vital for the rapid reorganization of cellular microtubule arrays and the release of microtubules from the centrosome following nucleation, facilitating poleward microtubule flux and chromosome motion during mitosis.
Therapeutic significance:
Understanding the role of Fidgetin could open doors to potential therapeutic strategies.